In collaboration with the European clinical research team NISCI (www.nisci-2020.eu), we conducted a clinical trial with human anti-human antibodies against Nogo-A in acutely injured tetraplegic patients. Anti-Nogo-A antibody was proven to be safe, well tolerable and feasible, and the pharmacokinetics showed no abnormalities (Kucher et al., 2018). Based on these promising results, a placebo-controlled phase 2 “proof-of-concept” study is currently conducted in a number of leading European spinal cord injury centers.
For details on the clinical phase I study please consider the following website: http://www.nisci-2020.eu
Click on the "SF Videoportal" link: SF Videoportal
See the following video: